Prescient Therapeutics’ PTX-100 trial expands to top US cancer centre
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics has crossed a major milestone in its international expansion, with the first US...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.